Abstract:Background: Current hypertension guidelines recommend combination of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker with a calcium-channel blocker or thiazide diuretic as initial antihypertensive therapy in patients with monotherapy uncontrolled hypertension. However, to what extent these two different combinations are comparable in blood pressure (BP)-lowering efficacy and safety remains under investigation, especially in the Chinese population. We investigated the BP-lowering efficacy and safety of the amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies in Chinese patients. Methods: In a multi-center, randomized, actively controlled, parallel-group trial, we enrolled patients with stage 1 or 2 hypertension from July 2018 to June 2021 in 20 hospitals and community health centers across China. Of the 894 screened patients, 560 eligible patients were randomly assigned to amlodipine/benazepril 5/10 mg (n = 282) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 278), with 213 and 212 patients, respectively, who completed the study and had a valid repeat ambulatory BP recording during follow-up and were included in the efficacy analysis. The primary outcome was the change from baseline to 24 weeks of treatment in 24-h ambulatory systolic BP. Adverse events including symptoms and clinically significant changes in physical examinations and laboratory findings were recorded for safety analysis. Results: In the efficacy analysis (n = 425), the primary outcome, 24-h ambulatory systolic BP reduction, was - 13.8 ± 1.2 mmHg in the amlodipine/benazepril group and - 12.3 ± 1.2 mmHg in the benazepril/hydrochlorothiazide group, with a between-group difference of - 1.51 (p = 0.36) mmHg. The between-group differences for major secondary outcomes were - 1.47 (p = 0.18) in 24-h diastolic BP, - 2.86 (p = 0.13) and - 2.74 (p = 0.03) in daytime systolic and diastolic BP, and - 0.45 (p = 0.82) and - 0.93 (p = 0.44) in nighttime systolic and diastolic BP. In the safety analysis (n = 560), the incidence rate of dry cough was significantly lower in the amlodipine/benazepril group than in the benazepril/hydrochlorothiazide group (5.3% vs 10.1%, p = 0.04). Conclusions: The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering. The former combination, compared with the latter, had a greater BP-lowering effect in the daytime and a lower incidence rate of dry cough. Trial registration: ClinicalTrials.gov, NCT03682692. Registered on 18 September 2018.

A meta-analysis of anti-hypertensive efficacy and safety between cilnidipine and amlodipine

Double-blind Double-Dummy Randomized Controlled Multicenter Clinical Trial of Domestic Cilnidipine on Treatment of Essential Hypertension

Observation of Clinical Efficacy and Safety of Mild and Moderate Primary Hypertension Treated with Cilnidipine

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

A Meta-analysis on efficacy and safety of manidipine on hypertension

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients with Stable Angina Pectoris in China

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

CEA Comprehensive Evaluation for Western and Traditional Chinese Hypotensive Drugs

Comparison of anti-anginal effect of cilnidipine with those of nicardipine and nifedipine in the vasopressin-induced angina model of rats

Multicenter clinical trial on benidipine in the treatment of hypertension

Meta-analysis of Effectiveness and Safety of Levoamlodipine and Amlodipine for Essential Hypertension

The Efficacy and Safety of Amlodipine Maleate on Patients with Mild to Moderate Essential Hypertension

A Retrospective Cost-Effectiveness Analysis of S-Amlodipine in China.

Effect of nifedipine controlled released tablet and atorvastatin on carotid intimamedia thickness and vascular endothelial function in patients with hypertension

Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis

The Effectiveness and Safety of L-amlodipine Besylate for Blood Pressure Control in Patients with Mild to Moderate Essential Hypertension

Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction

Study of the Anti-Hypertensive Efficacy and Safety of Benidipine in Patients with Essential Hypertension

Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine

Comparison of Beijing Anti-hypertension 0 and Amlodiping in Treatment Essential Hypertension

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial